852
Participants
Start Date
April 3, 2019
Primary Completion Date
August 17, 2021
Study Completion Date
July 11, 2022
Bimekizumab
Subjects will receive bimekizumab at pre-specified time-points.
Adalimumab
Adalimumab will be administered according to the labeling recommendations.
Placebo
Subjects will receive placebo at pre-specified time-points.
Pa0010 50010, Brooklyn
Pa0010 50020, Duncansville
Pa0010 50006, Wyomissing
Pa0010 50015, Hagerstown
Pa0010 50050, Beckley
Pa0010 50125, Charlotte
Pa0010 50007, Orangeburg
Pa0010 50039, Atlanta
Pa0010 50037, Tampa
Pa0010 50033, Palm Harbor
Pa0010 50012, Memphis
Pa0010 50001, Jackson
Pa0010 50028, Lexington
Pa0010 50040, Dayton
Pa0010 50016, St Louis
Pa0010 50036, Mesquite
Pa0010 50009, Waco
Pa0010 50051, Houston
Pa0010 50049, Corpus Christi
Pa0010 50002, Austin
Pa0010 50017, Phoenix
Pa0010 50029, Albuquerque
Pa0010 50035, San Diego
Pa0010 50004, Tustin
Pa0010 50008, Johnston
Pa0010 30005, Camberwell
Pa0010 30002, Clayton
Pa0010 30008, Hobart
Pa0010 30003, Maroochydore
Pa0010 30007, Victoria Park
Pa0010 30006, Woodville
Pa0010 40003, Genk
Pa0010 40002, Leuven
Pa0010 40059, Mons
Pa0010 50041, Québec
Pa0010 50042, Rimouski
Pa0010 50043, Sidney
Pa0010 50044, Trois-Rivières
Pa0010 40061, Brno
Pa0010 40065, Brno
Pa0010 40062, Ostrava
Pa0010 40009, Pardubice
Pa0010 40013, Prague
Pa0010 40014, Prague
Pa0010 40015, Prague
Pa0010 40063, Prague
Pa0010 40066, Prague
Pa0010 40010, Uherské Hradiště
Pa0010 40012, Zlín
Pa0010 40019, Paris
Pa0010 40068, Tours
Pa0010 40074, Bad Doberan
Pa0010 40025, Berlin
Pa0010 40028, Berlin
Pa0010 40076, Cottbus
Pa0010 40023, Erlangen
Pa0010 40117, Frankfurt
Pa0010 40029, Hamburg
Pa0010 40071, Hamburg
Pa0010 40027, Herne
Pa0010 40078, Leipzig
Pa0010 40348, Magdeburg
Pa0010 40026, Ratingen
Pa0010 40081, Budapest
Pa0010 40083, Budapest
Pa0010 40032, Debrecen
Pa0010 40030, Eger
Pa0010 40082, Kistarcsa
Pa0010 40079, Szentes
Pa0010 40033, Székesfehérvár
Pa0010 40080, Szombathely
Pa0010 40084, Catania
Pa0010 40087, Milan
Pa0010 40085, Pisa
Pa0010 40086, Reggio Emilia
Pa0010 20035, Bunkyō City
Pa0010 20036, Kawachi-Nagano-shi
Pa0010 20045, Kita-ku
Pa0010 20049, Kitakyushu
Pa0010 20044, Minatoku
Pa0010 20033, Nagoya
Pa0010 20041, Osaka
Pa0010 20046, Osaka
Pa0010 20048, Saitama
Pa0010 20031, Sapporo
Pa0010 20042, Sasebo
Pa0010 20032, Suita
Pa0010 20043, tabashi City
Pa0010 20030, Tokyo
Pa0010 40093, Bialystok
Pa0010 40119, Bydgoszcz
Pa0010 40038, Elblag
Pa0010 40088, Elblag
Pa0010 40096, Gdynia
Pa0010 40042, Krakow
Pa0010 40092, Krakow
Pa0010 40037, Lublin
Pa0010 40091, Nowa Sól
Pa0010 40044, Poznan
Pa0010 40090, Poznan
Pa0010 40118, Torun
Pa0010 40041, Warsaw
Pa0010 40094, Warsaw
Pa0010 40097, Warsaw
Pa0010 40098, Warsaw
Pa0010 40039, Wroclaw
Pa0010 40043, Wroclaw
Pa0010 40095, Wroclaw
Pa0010 20002, Moscow
Pa0010 20005, Moscow
Pa0010 20010, Moscow
Pa0010 20017, Moscow
Pa0010 20013, Petrozavodsk
Pa0010 20012, Ryazan
Pa0010 20016, Ryazan
Pa0010 20001, Saint Petersburg
Pa0010 20003, Saint Petersburg
Pa0010 20004, Saint Petersburg
Pa0010 20009, Saint Petersburg
Pa0010 20083, Saint Petersburg
Pa0010 20007, Saratov
Pa0010 20014, Ulyanovsk
Pa0010 20006, Vladimir
Pa0010 20008, Yaroslavl
Pa0010 20015, Yaroslavl
Pa0010 40045, A Coruña
Pa0010 40105, Córdoba
Pa0010 40102, Málaga
Pa0010 40101, Sabadell
Pa0010 40104, Santiago de Compostela
Pa0010 40049, Seville
Pa0010 40103, Seville
Pa0010 40106, Seville
Pa0010 40099, Vigo
Pa0010 40111, Leeds
Pa0010 40107, Wolverhampton
UCB Biopharma SRL
INDUSTRY